Michele Jara
About Michele Jara
Michele Jara serves as the Senior Director of Risk Management and Epidemiology at Aimmune Therapeutics, a position she has held since 2022. With extensive experience in epidemiology and risk management across various organizations, she has contributed significantly to the field over her career.
Work at Aimmune Therapeutics
Michele Jara has been serving as the Senior Director of Risk Management and Epidemiology at Aimmune Therapeutics since 2022. In this role, she focuses on overseeing risk management strategies and epidemiological studies to support the company's therapeutic developments. Prior to her current position, she held various roles at Acorda Therapeutics, including Executive Director of Risk Management and Epidemiology and Senior Director of Epidemiology.
Previous Experience in Risk Management and Epidemiology
Before joining Aimmune Therapeutics, Michele Jara worked at Acorda Therapeutics, Inc. in multiple capacities, including Senior Director of Risk Management and Epidemiology from 2017 to 2018 and Executive Director from 2018 to 2021. She also served as Associate Director of Global Pharmacovigilance and Epidemiology at sanofi-aventis from 2009 to 2011. Her extensive experience in the field includes a significant tenure at the Massachusetts Department of Public Health as an Epidemiologist.
Educational Background in Epidemiology
Michele Jara earned her Master of Public Health (MPH) and Doctor of Science (D.Sc.) degrees in Epidemiology/Biostatistics from Boston University. She also holds a Bachelor of Science (BS) degree in Biology from Saint Michael's College. Her educational background provides a strong foundation for her work in epidemiology and risk management.
Career in Epidemiology
Michele Jara has a long-standing career in epidemiology, beginning as an Epidemiologist at the Massachusetts Department of Public Health from 1992 to 2003. She later worked at Boehringer Ingelheim as Senior Associate Director of Epidemiology from 2004 to 2009, and at Acorda Therapeutics, Inc. in various roles related to epidemiology from 2011 to 2018. Her career reflects a commitment to advancing the field of epidemiology through various leadership positions.